Home › Research › Cognitive tests and assessment
Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial
Rosenberg PB, Lanctôt KL, Drye LT, Herrmann N, Scherer RW, Bachman DL, Mintzer JE, ADMET Investigators.. The Journal of clinical psychiatry, 2013-08-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective In a recent crossover trial, methylphenidate treatment decreased apathy in Alzheimer's disease. We further assessed this finding in the Apathy in Dementia Methylphenidate Trial (ADMET). Method Six-week, randomized, double-blind, placebo-controlled multicenter trial enrolling Alzheimer's disease participants (NINCDS-ADRDA criteria) with apathy assigned to methylphenidate 20 mg daily or placebo, conducted from June 2010 to December 2011.
What this study adds
Evidence grade: High
This is a trial of 37 participants. This six-week randomized, double-blind, placebo-controlled trial assessed methylphenidate 20 mg daily versus placebo for apathy in people with Alzheimer's disease. It is about treating apathy as a symptom and does not show any effect on curing or preventing Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rosenberg, P. B., Lanctôt, K. L., Drye, L. T., Herrmann, N., Scherer, R. W., Bachman, D. L., et al. (2013). Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. The Journal of clinical psychiatry. https://doi.org/10.4088/jcp.12m08099
Vancouver
Rosenberg PB, Lanctôt KL, Drye LT, Herrmann N, Scherer RW, Bachman DL, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. The Journal of clinical psychiatry. 2013. doi:10.4088/jcp.12m08099. PMID: 24021498.
BibTeX
@article{rosenberg2013-24021498,
author = {Rosenberg, P. B. and Lanctôt, K. L. and Drye, L. T. and Herrmann, N. and Scherer, R. W. and Bachman, D. L. and Mintzer, J. E. and {ADMET Investigators}},
title = {{Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial}},
journal = {The Journal of clinical psychiatry},
year = {2013},
doi = {10.4088/jcp.12m08099},
pmid = {24021498},
url = {https://doi.org/10.4088/jcp.12m08099}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- We further assessed this finding in the Apathy in Dementia Methylphenidate Trial (ADMET).
- Method Six-week, randomized, double-blind, placebo-controlled multicenter trial enrolling Alzheimer's disease participants (NINCDS-ADRDA criteria) with apathy assigned to methylphenidate 20 mg daily or placebo, conducted from June 2010 to December 2011.
- Primary outcomes were change in Apathy Evaluation Scale (AES) score and modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGI-C).
- Secondary outcomes included change in Neuropsychiatric Inventory (NPI) apathy score, Mini-Mental State Examination (MMSE) score, and safety.
Why it matters
This six-week randomized, double-blind, placebo-controlled trial assessed methylphenidate 20 mg daily versus placebo for apathy in people with Alzheimer's disease. It is about treating apathy as a symptom and does not show any effect on curing or preventing Alzheimer's disease.
Study details
- Participants37
- Evidence strengthHigh
How this study scored 67/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 64 of the 96 points we could judge it on, which is 67 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of clinical psychiatry) |
| Journal's citation record | 2 / 4 | The Journal of Clinical Psychiatry: journal h-index 248 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2013 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 37 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 5 / 7 | Cited 189 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 12.6 citations a year over 15 year(s) since 2013 |
| Impact for its field and year | 4 / 6 | Cited 8.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 2 / 4 | Cited 30 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 2 / 3 | Johns Hopkins University: institution h-index 2,306 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 24021498) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 64 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 64 of the 96 points we could judge it on is 67 out of 100. |
| Total | 67 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.